The AIDS Clinical Trials Unit (ACTU) at Massachusetts General Hospital is seeking HIV-1 and Hepatitis C co-infected individuals over the age of 18 to participate in a research study. The study will look at a new treatment for people with insulin resistance who have not responded to previous peginteferon/ribavirin therapy. Subjects will receive Actos for the first 24 weeks then add peginteferon/ribavirin therapy for an additional 48 weeks. To qualify you must have a CD4 count ¡Ý200, have HCV genotype 1 virus, currently on stable HIV treatment for 12 weeks or no treatment, and are Hepatitis A or B negative.

The study will last about one and a half years and will involve about 20 outpatient visits. Actos, peginterferon and ribavirin will be provided through the study.

You will receive $20.00 per study visit as well as reimbursement for parking and transportation.

For more information please contact Amy Sbrolla, RN or Nicole Burgett, RN at 617-726-3819.

Institution  –  MGH - Massachusetts General Hospital, Boston, MA

Principal Investigator  – Arthur Kim, MD

  

For further information about enrolling a patient in this trial, contact the person below.

Name  – Nicole Burgett-Yandow, RN

Phone  – 617-726-3819